Search for Molecular Biomarkers of Parkinson’s Disease. New Tissues and Methods

1. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009; 8(12):1150–7. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009; 8(12):1150–7.Search in Google Scholar

2. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9(1):13–24. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013; 9(1):13–24.Search in Google Scholar

3. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet 2021; 397(10291):2284-2303. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet 2021; 397(10291):2284-2303.Search in Google Scholar

4. Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson’s disease: Contributions and global trends. J Hum Genet 2023; 68(3):125-130. Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson’s disease: Contributions and global trends. J Hum Genet 2023; 68(3):125-130.Search in Google Scholar

5. Berg D, Borghammer P, Fereshtehnejad SM, Heinzel S, Horsager J, Schaeffer E, Postuma RB. Prodromal Parkinson disease subtypes – key to understanding heterogeneity. Nat Rev Neurol 2021; 17(6):349-361. Berg D, Borghammer P, Fereshtehnejad SM, Heinzel S, Horsager J, Schaeffer E, Postuma RB. Prodromal Parkinson disease subtypes – key to understanding heterogeneity. Nat Rev Neurol 2021; 17(6):349-361.Search in Google Scholar

6. Tönges L, Buhmann C, Klebe S, Klucken J, Kwon EH, Müller T, Pedrosa DJ, Schröter N, Riederer P, Lingor P. Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice. J Neural Transm (Vienna) 2022; 129(9):1201-1217. Tönges L, Buhmann C, Klebe S, Klucken J, Kwon EH, Müller T, Pedrosa DJ, Schröter N, Riederer P, Lingor P. Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice. J Neural Transm (Vienna) 2022; 129(9):1201-1217.Search in Google Scholar

7. Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2(2): a009399. Stefanis L. α-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2(2): a009399.Search in Google Scholar

8. Jęśko H, Lenkiewicz AM, Wilkaniec A, Adamczyk A. The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson’s disease. Acta Neurobiol Exp (Wars) 2019; 79(3):276-289. Jęśko H, Lenkiewicz AM, Wilkaniec A, Adamczyk A. The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson’s disease. Acta Neurobiol Exp (Wars) 2019; 79(3):276-289.Search in Google Scholar

9. Ganguly U, Singh S, Pal S, Prasad S, Agrawal BK, Saini RV, Chakrabarti S. Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough. Front Aging Neurosci. 2021; 13:702639. Ganguly U, Singh S, Pal S, Prasad S, Agrawal BK, Saini RV, Chakrabarti S. Alpha-Synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough. Front Aging Neurosci. 2021; 13:702639.Search in Google Scholar

10. Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF. Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. NPJ Parkinsons Dis 2021; 7(1):65. Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF. Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. NPJ Parkinsons Dis 2021; 7(1):65.Search in Google Scholar

11. Magalhães P, Lashuel HA. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies. NPJ Parkinsons Dis 2022; 8(1):93. Magalhães P, Lashuel HA. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies. NPJ Parkinsons Dis 2022; 8(1):93.Search in Google Scholar

12. Bu J, Liu J, Liu K, Wang Z. Diagnostic utility of gut α-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Behav Brain Res 2019; 364:340-347. Bu J, Liu J, Liu K, Wang Z. Diagnostic utility of gut α-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Behav Brain Res 2019; 364:340-347.Search in Google Scholar

13. Tsukita K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, Takahashi R. Value of in vivo α-synuclein deposits in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 2019; 34(10):1452-1463. Tsukita K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, Takahashi R. Value of in vivo α-synuclein deposits in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 2019; 34(10):1452-1463.Search in Google Scholar

14. Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orrú CD, Tatsuoka C, Liguori R, Gunzler SA, Caughey B, Jimenez-Capdeville ME, Zhu X, Doppler K, Cui L, Chen SG, Ma J, Zou WQ. Skin -Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol 2020; 78(1):1–11. Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orrú CD, Tatsuoka C, Liguori R, Gunzler SA, Caughey B, Jimenez-Capdeville ME, Zhu X, Doppler K, Cui L, Chen SG, Ma J, Zou WQ. Skin -Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol 2020; 78(1):1–11.Search in Google Scholar

15. Doppler K. Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson’s Disease. J Parkinsons Dis 2021; 11(3):937-947. Doppler K. Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson’s Disease. J Parkinsons Dis 2021; 11(3):937-947.Search in Google Scholar

16. Han Y, Wu D, Wang Y, Xie J, Zhang Z. Skin alpha-synuclein deposit patterns: A predictor of Parkinson’s disease subtypes. EBioMedicine 2022; 80:104076. Han Y, Wu D, Wang Y, Xie J, Zhang Z. Skin alpha-synuclein deposit patterns: A predictor of Parkinson’s disease subtypes. EBioMedicine 2022; 80:104076.Search in Google Scholar

17. Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M, Calabresi P, Parnetti L. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 2017; 32(10):1389-1400. Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M, Calabresi P, Parnetti L. Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 2017; 32(10):1389-1400.Search in Google Scholar

18. Martinez-Valbuena I, Visanji NP, Olszewska DA, Sousa M, Bhakta P, Vasilevskaya A, Anastassiadis C, Tartaglia MC, Kovacs GG, Lang AE. Combining Skin -Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson’s Disease. Mov Disord 2022; 37(3):648-650. Martinez-Valbuena I, Visanji NP, Olszewska DA, Sousa M, Bhakta P, Vasilevskaya A, Anastassiadis C, Tartaglia MC, Kovacs GG, Lang AE. Combining Skin -Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson’s Disease. Mov Disord 2022; 37(3):648-650.Search in Google Scholar

19. Xiang C, Cong S, Tan X, Ma S, Liu Y, Wang H, Cong S. A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease. NPJ Parkinsons Dis 2022; 8(1):165. Xiang C, Cong S, Tan X, Ma S, Liu Y, Wang H, Cong S. A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease. NPJ Parkinsons Dis 2022; 8(1):165.Search in Google Scholar

20. Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, Trenkwalder C, Sixel-Döring F, Foubert-Samier A, Pavy-Le Traon A, Plazzi G, Biscarini F, Montplaisir J, Gagnon JF, Postuma RB, Antelmi E, Meissner WG, Mollenhauer B, Ben-Shlomo Y, Hu MT, Parkkinen L. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 2022; 145(2):584-595. Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, Trenkwalder C, Sixel-Döring F, Foubert-Samier A, Pavy-Le Traon A, Plazzi G, Biscarini F, Montplaisir J, Gagnon JF, Postuma RB, Antelmi E, Meissner WG, Mollenhauer B, Ben-Shlomo Y, Hu MT, Parkkinen L. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 2022; 145(2):584-595.Search in Google Scholar

21. Antelmi E, Donadio V, Incensi A, Plazzi G, Liguori R. Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder. Neurology 2017; 88(22):2128-2131. Antelmi E, Donadio V, Incensi A, Plazzi G, Liguori R. Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder. Neurology 2017; 88(22):2128-2131.Search in Google Scholar

22. Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 2017; 133(4):535-545. Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 2017; 133(4):535-545.Search in Google Scholar

23. Vilas D, Iranzo A, Tolosa E, Aldecoa I, Berenguer J, Vilaseca I, Martí C, Serradell M, Lomeña F, Alós L, Gaig C, Santamaria J, Gelpi E. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 2016; 15(7):708-718. Vilas D, Iranzo A, Tolosa E, Aldecoa I, Berenguer J, Vilaseca I, Martí C, Serradell M, Lomeña F, Alós L, Gaig C, Santamaria J, Gelpi E. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 2016; 15(7):708-718.Search in Google Scholar

24. Iranzo A, Borrego S, Vilaseca I, Martí C, Serradell M, Sánchez-Valle R, Kovacs GG, Valldeoriola F, Gaig C, Santamaria J, Tolosa E, Gelpi E. α-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder. Sleep. 2018 Aug 1;41(8). doi: 10.1093/sleep/zsy101.Klatt S, Doecke JD, Roberts A, Boughton BA, Masters CL, Horne M, Roberts BR. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease. NPJ Parkinsons Dis 2021; 7(1):94. Iranzo A, Borrego S, Vilaseca I, Martí C, Serradell M, Sánchez-Valle R, Kovacs GG, Valldeoriola F, Gaig C, Santamaria J, Tolosa E, Gelpi E. α-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder. Sleep. 2018 Aug 1;41(8). doi: 10.1093/sleep/zsy101.Klatt S, Doecke JD, Roberts A, Boughton BA, Masters CL, Horne M, Roberts BR. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease. NPJ Parkinsons Dis 2021; 7(1):94.Open DOI Search in Google Scholar

25. Sprenger FS, Stefanova N, Gelpi E, Seppi K, Navarro-Otano J, Offner F, Vilas D, Valldeoriola F, Pont-Sunyer C, Aldecoa I, Gaig C, Gines A, Cuatrecasas M, Högl B, Frauscher B, Iranzo A, Wenning GK, Vogel W, Tolosa E, Poewe W. Enteric nervous system -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology 2015; 85(20):1761-8. Sprenger FS, Stefanova N, Gelpi E, Seppi K, Navarro-Otano J, Offner F, Vilas D, Valldeoriola F, Pont-Sunyer C, Aldecoa I, Gaig C, Gines A, Cuatrecasas M, Högl B, Frauscher B, Iranzo A, Wenning GK, Vogel W, Tolosa E, Poewe W. Enteric nervous system -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology 2015; 85(20):1761-8.Search in Google Scholar

26. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008; 5(2):55-9. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 2008; 5(2):55-9.Search in Google Scholar

27. Vivacqua G, Mason M, De Bartolo MI, Węgrzynowicz M, Calò L, Belvisi D, Suppa A, Fabbrini G, Berardelli A, Spillantini M. Salivary α-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson’s Disease. Mov Disord 2023; 38(1):153-5. Vivacqua G, Mason M, De Bartolo MI, Węgrzynowicz M, Calò L, Belvisi D, Suppa A, Fabbrini G, Berardelli A, Spillantini M. Salivary α-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson’s Disease. Mov Disord 2023; 38(1):153-5.Search in Google Scholar

28. Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, Bhatia K, Morris HR, Giunti P, Warner TT, de Silva R, Lees AJ, Zetterberg H. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015; 86(11):1240-7. Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, Bhatia K, Morris HR, Giunti P, Warner TT, de Silva R, Lees AJ, Zetterberg H. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015; 86(11):1240-7.Search in Google Scholar

29. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group; Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 2019; 76(9):1035-1048. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group; Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 2019; 76(9):1035-1048.Search in Google Scholar

30. Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology 2019; 93(11):e1104-e1111. Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ. Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology 2019; 93(11):e1104-e1111.Search in Google Scholar

31. Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K; Swedish BioFINDER study. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 2017; 88(10):930-937. Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K; Swedish BioFINDER study. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 2017; 88(10):930-937.Search in Google Scholar

32. Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, Otto M, Verbeek MM. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 2019; 92(13):e1479-e1486. Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, Otto M, Verbeek MM. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 2019; 92(13):e1479-e1486.Search in Google Scholar

33. Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression. Mov Disord 2020; 35(11):1999-2008. Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression. Mov Disord 2020; 35(11):1999-2008.Search in Google Scholar

34. Niemann L, Lezius S, Maceski A, Leppert D, Englisch C, Schwedhelm E, Zeller T, Gerloff C, Kuhle J, Choe CU. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson’s disease (MARK-PD). Parkinsonism Relat Disord 2021; 90:44-48. Niemann L, Lezius S, Maceski A, Leppert D, Englisch C, Schwedhelm E, Zeller T, Gerloff C, Kuhle J, Choe CU. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson’s disease (MARK-PD). Parkinsonism Relat Disord 2021; 90:44-48.Search in Google Scholar

35. Liu Y, Dou K, Xue L, Li X, Xie A. Neurofilament light as a biomarker for motor decline in Parkinson’s disease. Front Neurosci 2022; 16:959261. Liu Y, Dou K, Xue L, Li X, Xie A. Neurofilament light as a biomarker for motor decline in Parkinson’s disease. Front Neurosci 2022; 16:959261.Search in Google Scholar

36. Oosterveld LP, Verberk IMW, Majbour NK, El-Agnaf OM, Weinstein HC, Berendse HW, Teunissen CE, van de Berg WDJ. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson’s from controls. Mov Disord 2020; 35(2):288-295. Oosterveld LP, Verberk IMW, Majbour NK, El-Agnaf OM, Weinstein HC, Berendse HW, Teunissen CE, van de Berg WDJ. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson’s from controls. Mov Disord 2020; 35(2):288-295.Search in Google Scholar

37. Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX, Trojanowski JQ, Shaw LM, Chen-Plotkin AS. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Mov Disord 2021; 36(12):2945-2950. Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX, Trojanowski JQ, Shaw LM, Chen-Plotkin AS. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Mov Disord 2021; 36(12):2945-2950.Search in Google Scholar

38. Gopinath A, Mackie P, Hashimi B, Buchanan AM, Smith AR, Bouchard R, Shaw G, Badov M, Saadatpour L, Gittis A, Ramirez-Zamora A, Okun MS, Streit WJ, Hashemi P, Khoshbouei H. DAT and TH expression marks human Parkinson’s disease in peripheral immune cells. NPJ Parkin sons Dis 2022; 8(1):72. Gopinath A, Mackie P, Hashimi B, Buchanan AM, Smith AR, Bouchard R, Shaw G, Badov M, Saadatpour L, Gittis A, Ramirez-Zamora A, Okun MS, Streit WJ, Hashemi P, Khoshbouei H. DAT and TH expression marks human Parkinson’s disease in peripheral immune cells. NPJ Parkin sons Dis 2022; 8(1):72.Search in Google Scholar

39. Gopinath A, Badov M, Francis M, Shaw G, Collins A, Miller DR, Hansen CA, Mackie P, Tansey MG, Dagra A, Madorsky I, Ramirez-Zamora A, Okun MS, Streit WJ, Khoshbouei H. TNF increases tyrosine hydroxylase expression in human monocytes. NPJ Parkinsons Dis 2021; 7(1):62. Gopinath A, Badov M, Francis M, Shaw G, Collins A, Miller DR, Hansen CA, Mackie P, Tansey MG, Dagra A, Madorsky I, Ramirez-Zamora A, Okun MS, Streit WJ, Khoshbouei H. TNF increases tyrosine hydroxylase expression in human monocytes. NPJ Parkinsons Dis 2021; 7(1):62.Search in Google Scholar

40. Zhang H, Yao L, Zheng Z, Koc S, Lu G. The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement. Pharmaceuticals (Basel) 2022; 15(7):811. Zhang H, Yao L, Zheng Z, Koc S, Lu G. The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement. Pharmaceuticals (Basel) 2022; 15(7):811.Search in Google Scholar

41. Ding H, Huang Z, Chen M, Wang C, Chen X, Chen J, Zhang J. Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease. Parkinsonism Relat Disord 2016; 22:68-73. Ding H, Huang Z, Chen M, Wang C, Chen X, Chen J, Zhang J. Identification of a panel of five serum miRNAs as a biomarker for Parkinson’s disease. Parkinsonism Relat Disord 2016; 22:68-73.Search in Google Scholar

42. Uwatoko H, Hama Y, Iwata IT, Shirai S, Matsushima M, Yabe I, Utsumi J, Sasaki H. Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson’s disease. Mol Brain 2019; 12(1):49. Uwatoko H, Hama Y, Iwata IT, Shirai S, Matsushima M, Yabe I, Utsumi J, Sasaki H. Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson’s disease. Mol Brain 2019; 12(1):49.Search in Google Scholar

43. Manna I, Quattrone A, De Benedittis S, Vescio B, Iaccino E, Quattrone A. Exosomal miRNA as peripheral biomarkers in Parkinson’s disease and progressive supranuclear palsy: A pilot study. Parkinsonism Relat Disord 2021; 93:77-84. Manna I, Quattrone A, De Benedittis S, Vescio B, Iaccino E, Quattrone A. Exosomal miRNA as peripheral biomarkers in Parkinson’s disease and progressive supranuclear palsy: A pilot study. Parkinsonism Relat Disord 2021; 93:77-84.Search in Google Scholar

44. Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RAJ, Bloem BR, Verbeek MM. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy. Mol Neurobiol 2017; 54(10):7736-7745. Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RAJ, Bloem BR, Verbeek MM. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy. Mol Neurobiol 2017; 54(10):7736-7745.Search in Google Scholar

45. Starhof C, Hejl AM, Heegaard NHH, Carlsen AL, Burton M, Lilje B, Winge K. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Mov Disord 2019; 34(2):246-254. Starhof C, Hejl AM, Heegaard NHH, Carlsen AL, Burton M, Lilje B, Winge K. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes. Mov Disord 2019; 34(2):246-254.Search in Google Scholar

46. Toomey CE, Heywood WE, Evans JR, Lachica J, Pressey SN, Foti SC, Al Shahrani M, D’Sa K, Hargreaves IP, Heales S, Orford M, Troakes C, Attems J, Gelpi E, Palkovits M, Lashley T, Gentleman SM, Revesz T, Mills K, Gandhi S. Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s. Acta Neuropathol Commun 2022; 10(1):134. Toomey CE, Heywood WE, Evans JR, Lachica J, Pressey SN, Foti SC, Al Shahrani M, D’Sa K, Hargreaves IP, Heales S, Orford M, Troakes C, Attems J, Gelpi E, Palkovits M, Lashley T, Gentleman SM, Revesz T, Mills K, Gandhi S. Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s. Acta Neuropathol Commun 2022; 10(1):134.Search in Google Scholar

47. Evinova A, Hatokova Z, Tatarkova Z, Brodnanova M, Dibdiakova K, Racay P. Endoplasmic reticulum stress induces mitochondrial dysfunction but not mitochondrial unfolded protein response in SH-SY5Y cells. Mol Cell Biochem 2022; 477(3):965-975. Evinova A, Hatokova Z, Tatarkova Z, Brodnanova M, Dibdiakova K, Racay P. Endoplasmic reticulum stress induces mitochondrial dysfunction but not mitochondrial unfolded protein response in SH-SY5Y cells. Mol Cell Biochem 2022; 477(3):965-975.Search in Google Scholar

48. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson’s disease. Biochem Biophys Res Commun 2007; 354(3):707-11. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W. Activation of the unfolded protein response in Parkinson’s disease. Biochem Biophys Res Commun 2007; 354(3):707-11.Search in Google Scholar

49. Baek JH, Mamula D, Tingstam B, Pereira M, He Y, Svenningsson P. GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson’s Disease Patients. Front Neurosci 2019; 13:697. Baek JH, Mamula D, Tingstam B, Pereira M, He Y, Svenningsson P. GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson’s Disease Patients. Front Neurosci 2019; 13:697.Search in Google Scholar

50. Mnich K, Moghaddam S, Browne P, Counihan T, Fitzgerald SP, Martin K, Richardson C, Samali A, Gorman AM. Endoplasmic Reticulum Stress-Regulated Chaperones as a Serum Biomarker Panel for Parkinson’s Disease. Mol Neurobiol 2023; 60(3):1476-1485. Mnich K, Moghaddam S, Browne P, Counihan T, Fitzgerald SP, Martin K, Richardson C, Samali A, Gorman AM. Endoplasmic Reticulum Stress-Regulated Chaperones as a Serum Biomarker Panel for Parkinson’s Disease. Mol Neurobiol 2023; 60(3):1476-1485.Search in Google Scholar

51. Chinopoulos C. Quantification of mitochondrial DNA from peripheral tissues: Limitations in predicting the severity of neurometabolic disorders and proposal of a novel diagnostic test. Mol Aspects Med 2020; 71:100834. Chinopoulos C. Quantification of mitochondrial DNA from peripheral tissues: Limitations in predicting the severity of neurometabolic disorders and proposal of a novel diagnostic test. Mol Aspects Med 2020; 71:100834.Search in Google Scholar

52. Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced mitochondrial DNA copy number is a biomarker of Parkinson’s disease. Neurobiol Aging 2016; 38:216.e7-216.e10. Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced mitochondrial DNA copy number is a biomarker of Parkinson’s disease. Neurobiol Aging 2016; 38:216.e7-216.e10.Search in Google Scholar

53. Delbarba A, Abate G, Prandelli C, Marziano M, Buizza L, Arce Varas N, Novelli A, Cuetos F, Martinez C, Lanni C, Memo M, Uberti D. Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer’s Disease and Mild Cognitive Impairment Patients. Oxid Med Cell Longev 2016; 2016:5923938. Delbarba A, Abate G, Prandelli C, Marziano M, Buizza L, Arce Varas N, Novelli A, Cuetos F, Martinez C, Lanni C, Memo M, Uberti D. Mitochondrial Alterations in Peripheral Mononuclear Blood Cells from Alzheimer’s Disease and Mild Cognitive Impairment Patients. Oxid Med Cell Longev 2016; 2016:5923938.Search in Google Scholar

54. Fiziková I, Račay P. Oxidative modifications of plasma proteins and decreased leukocyte mitochondrial DNA of schizophrenia patients. Act Nerv Super Rediviva 2022; 64(1): 25–32. Fiziková I, Račay P. Oxidative modifications of plasma proteins and decreased leukocyte mitochondrial DNA of schizophrenia patients. Act Nerv Super Rediviva 2022; 64(1): 25–32.Search in Google Scholar

55. Wang D, Li Z, Liu W, Zhou J, Ma X, Tang J, Chen X. Differential mitochondrial DNA copy number in three mood states of bipolar disorder. BMC Psychiatry 2018; 18(1):149. Wang D, Li Z, Liu W, Zhou J, Ma X, Tang J, Chen X. Differential mitochondrial DNA copy number in three mood states of bipolar disorder. BMC Psychiatry 2018; 18(1):149.Search in Google Scholar

56. Castellani CA, Longchamps RJ, Sun J, Guallar E, Arking DE. Thinking outside the nucleus: Mitochondrial DNA copy number in health and disease. Mitochondrion 2020; 53:214-223. Castellani CA, Longchamps RJ, Sun J, Guallar E, Arking DE. Thinking outside the nucleus: Mitochondrial DNA copy number in health and disease. Mitochondrion 2020; 53:214-223.Search in Google Scholar

57. Grünewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM. Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons. Ann Neurol 2016; 79(3): 366-78. Grünewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM. Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons. Ann Neurol 2016; 79(3): 366-78.Search in Google Scholar

58. Schirinzi T, Salvatori I, Zenuni H, Grillo P, Valle C, Martella G, Mercuri NB, Ferri A. Pattern of Mitochondrial Respiration in Peripheral Blood Cells of Patients with Parkinson’s Disease. Int J Mol Sci 2022; 23(18):10863. Schirinzi T, Salvatori I, Zenuni H, Grillo P, Valle C, Martella G, Mercuri NB, Ferri A. Pattern of Mitochondrial Respiration in Peripheral Blood Cells of Patients with Parkinson’s Disease. Int J Mol Sci 2022; 23(18):10863.Search in Google Scholar

59. Klatt S, Doecke JD, Roberts A, Boughton BA, Masters CL, Horne M, Roberts BR. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease. NPJ Parkinsons Dis 2021; 7(1):94. Klatt S, Doecke JD, Roberts A, Boughton BA, Masters CL, Horne M, Roberts BR. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease. NPJ Parkinsons Dis 2021; 7(1):94.Search in Google Scholar

60. Mackmull MT, Nagel L, Sesterhenn F, Muntel J, Grossbach J, Stalder P, Bruderer R, Reiter L, van de Berg WDJ, de Souza N, Beyer A, Picotti P. Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker. Nat Struct Mol Biol 2022; 29:978-989. Mackmull MT, Nagel L, Sesterhenn F, Muntel J, Grossbach J, Stalder P, Bruderer R, Reiter L, van de Berg WDJ, de Souza N, Beyer A, Picotti P. Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker. Nat Struct Mol Biol 2022; 29:978-989.Search in Google Scholar

61. Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson’s disease. Lancet Neurol 2018; 17(7):629-640. Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson’s disease. Lancet Neurol 2018; 17(7):629-640.Search in Google Scholar

62. Prange S, Theis H, Banwinkler M, van Eimeren T. Molecular Imaging in Parkinsonian Disorders-What’s New and Hot? Brain Sci 2022; 12(9):1146. Prange S, Theis H, Banwinkler M, van Eimeren T. Molecular Imaging in Parkinsonian Disorders-What’s New and Hot? Brain Sci 2022; 12(9):1146.Search in Google Scholar

eISSN:: 1338-4139
Lingua:: Inglese

Frequenza di pubblicazione:: 3 volte all'anno
Argomenti della rivista:: Medicine, Clinical Medicine, Internal Medicine, Cardiology

Feed RSS della rivista